XRTX MEXC RealStocks
Own real XRTX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1

Last updated: 2026-11-13 07:09:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
XORTX Therapeutics Inc. (XRTX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.88, with a market capitalization of $1.62M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.83 to $3.60. This page covers its latest market performance, valuation, price trends and company information.
$1.62M | |
$0.89 | |
$0.93 | |
$0.86 | |
$0.89 | |
16.78K | |
746.16K | |
-- | |
$3.60 | |
$0.83 | |
-- | |
-- |
XORTX Therapeutics Inc. (XRTX) last closed at $0.88 as of 2026-11-13 00:59:00, down 1.49% ($0.01) from the previous close of $0.89.
During the latest regular trading session, XRTX traded between $0.86 and $0.93, with a volume of 16.78K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, XORTX Therapeutics Inc. (XRTX) moved from $0.99 to $0.88, representing a decline of 11.21% ($0.11).
The stock traded between $0.83 and $1.03 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 111.08 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.8%
XRTX is currently trading at $0.88, placing it 1.8% of the way from its 52-week low of $0.83 to its 52-week high of $3.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
| Employees | 3 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for XORTX Therapeutics Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of XORTX Therapeutics Inc. (XRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to XRTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between XRTX shares and USD.
XRTX Shares to USD
1.00 XRTX shares = 0.879 USD
Calculations are estimates based on the latest available price and are for reference only.